The latest update is out from OmniAb ( (OABI) ).
On April 18, 2025, OmniAb, Inc. appointed Steven C. Crouse and Philip J. Gotwals, Ph.D. as Class II directors to its Board, with terms expiring in 2027. Mr. Crouse, with over 20 years of experience in life sciences, joins the Audit and Science and Technology Committees, while Dr. Gotwals, with 30 years in biopharmaceuticals, joins the Human Capital Management and Compensation and Science and Technology Committees. Both were granted restricted stock units and options as part of their compensation. Concurrently, Sarah Boyce resigned from the Board, which expanded from six to seven members.
Spark’s Take on OABI Stock
According to Spark, TipRanks’ AI Analyst, OABI is a Neutral.
OmniAb is facing significant financial challenges with declining revenues and persistent losses. While the company shows potential through its strong pipeline and growth in partnerships, these positives are offset by technical indicators suggesting bearish momentum. The valuation is unattractive due to the negative P/E ratio and lack of dividends. Overall, the stock’s score reflects these mixed signals, with financial performance being the most significant factor.
To see Spark’s full report on OABI stock, click here.
More about OmniAb
YTD Price Performance: -48.86%
Average Trading Volume: 748,050
Technical Sentiment Signal: Buy
Current Market Cap: $218.6M
See more insights into OABI stock on TipRanks’ Stock Analysis page.